Update on the clinical use of the low-molecular-weight heparin, parnaparin by Camporese, Giuseppe et al.
© 2009 Camporese et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 819–831
Vascular Health and Risk Management
819
R e V i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Update on the clinical use of the low-molecular-
weight heparin, parnaparin
Giuseppe Camporese1 
enrico Bernardi2 
Franco Noventa3
1Unit of Angiology and 3Department 
of Clinical and experimental 
Medicine, Clinical epidemiology 
Group, University Hospital of Padua, 
italy; 2Department of emergency 
and Accident Medicine, Hospital of 
Conegliano Veneto, italy
Correspondence: Giuseppe Camporese 
Unit of Angiology, University Hospital of 
Padua, Via Giustiniani,  
2; 35128 – Padua, italy 
Tel +39 49-8212838/2932/2933 
Fax +39 49-8218739 
email giuseppe.camporese@sanita.
padova.it
Abstract: Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and 
safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, 
and in the treatment of venous and arterial (stable and unstable angina, acute ST-segment elevation 
myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 
12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcuta-
neously by means of once-daily regimen and is better tolerated than unfractionated heparin at the 
injection site. In the variety of commercially available low-molecular-weight heparins, parnaparin 
represents a useful therapeutic option, even though little evidence is available comparing the supe-
riority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or 
placebo. This review summarizes the available literature on the use of parnaparin in different settings 
of cardiovascular diseases, including papers published during the past year and ongoing studies.
Keywords: low-molecular-weight heparin, heparin, parnaparin, acute coronary syndromes, 
venous thromboembolism
Introduction
Anticoagulant therapy, such as heparin, has been used for at least 40 years in the 
management of chronic venous disorders and plays an important role in the prevention 
and treatment of venous and arterial thrombosis.1 Low-molecular-weight heparins 
(LMWHs) have been extensively investigated in a large number of randomized clinical 
trials. Where shown to be safe and effective they have been used as drugs for the 
prevention and treatment of venous thromboembolism (VTE), and for the treatment 
of acute coronary syndromes (ACS) and peripheral arterial occlusive disease (PAOD), 
and for the management of chronic venous disorders (CVD), including chronic venous 
insufficiency (secondary to post-thrombotic syndrome or varicose disease), and 
varicophlebitis or thrombophlebitis of nonvaricose veins.
Among other LMWHs, parnaparin (parnaparin sodium; Fluxum™)1 has been 
successfully employed for the prevention and the treatment of VTE and CVD, while its 
use in the management of ACS and PAOD has been less extensively investigated.2–4
The present review focuses on the pharmacological properties and clinical uses 
of parnaparin, especially in the management of venous thromboembolism, chronic 
venous disease, PAOD, and coronary artery disease.
Note on dosage
Dosages of parnaparin reported in this review (3200, 4250, 6400 and 12800 IUaXa) 
were calculated according to the European Pharmacopea Standard of LMWHs, and Vascular Health and Risk Management 2009:5 820
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are equivalent to those reported in clinical papers published 
between the early 1980s and the mid 1990s (7500, 10000, 
15000 and 30000 aXaU, respectively), which in turn were 
based on the 4th International Standard of Unfractionated 
Heparin (UFH).
Pharmacology of parnaparin
Pharmacodynamics
Parnaparin is a LMWH with a mean molecular weight 
of approximately 4.5 kDa, obtained with a specific 
fragmentation procedure that warrants the homogeneity 
of each fragment in terms of molecular weight and length, 
in order to optimize and maintain an anti-Xa/anti-IIa ratio 
of 4.3,5 The pharmacodynamics of subcutaneous parnaparin 
were investigated in studies in vitro, in healthy volunteers; 
and in patients with peripheral vascular diseases, acute 
coronary syndromes and undergoing surgery.
By in vitro studies, parnaparin was shown to possess the 
following properties:
–  inhibition of the thrombin activatable fibrinolytic 
inhibitor (TAFI) less potently than UFH (with inhibition of 50% 
of relative concentrations [IC50] of 0.6 to 0.8 vs 0.01 U/mL, 
respectively), similarly to dalteparin and tinzaparin, and more 
potently than enoxaparin (IC50  1.0 U/mL);6
–  active control of the anticoagulant effect in the 
presence of activated platelets, greater than UFH and inde-
pendent of the concomitant intake of aspirin;7
–  inhibition of aggregate formation of platelets/
polymorphonuclear leukocytes and of the expression of tissue 
factor and L-selectin in leukocytes; prevention of leukocyte 
degranulation and of fibrinogen binding to platelets more 
potently than UFH and enoxaparin.8,9
Studies in healthy volunteers showed that parnaparin 
inhibits factor Xa (antithrombotic effect) more efficiently than 
factor IIa (anticoagulant effect), resulting in a greater anti-Xa/
anti-IIa activity ratio than UFH.10–12 The inhibition of factor Xa 
occurs intensively and rapidly (anti-Xa activity about 0.2, 0.5 
and 0.9 aXaU/mL, approximatively 2 to 4 hours after 
administration of parnaparin 3200, 6400 and 12800 IUaXa, 
respectively), is dose-dependent, and persists for many 
hours after administration of a single bolus of subcutaneous 
parnaparin (ranging from 6 to 12 hours after administration 
of parnaparin 3200 or 6400 IUaXa, with demonstrable 
anti-Xa activity still occurring at 20 hours with the parnapa-
rin 6400 IUaXa dose; in contrast, the anti-IIa activity was 
undetectable at 4, 8 and 12 hours postadministration).11
Clinical studies conducted in patients undergoing 
bariatric surgery reported that the obesity (BMI  45 kg/m2) 
does not influence parnaparin anti-Xa activity.13 When 
fixed-dose parnaparin is employed as thromboprophylaxis 
in obese patients, a strong negative correlation between total 
body weight and anti-factor Xa levels is observed. These 
findings suggest that weight-based prophylactic dosing 
might be preferable to fixed-dosing for obese patients, and 
especially those with severe obesity (BMI 52.4 kg/m2).14 
A similar anti-factor Xa activity inhibitory effect, greater 
than UFH, is reported both in patients undergoing surgery15–17 
and in patients with a peripheral arterial occlusive disease 
(PAOD).18 Moreover, in PAOD and surgical patients, as in 
patients with acute myocardial infarction (MI), parnaparin 
has been shown to have a weak effect on activated partial 
thromboplastin time (aPTT) (only the highest dose of 12,800 
IU aXa caused a peak value reaching the lower limit of 
clinical significance),10,11 to decrease fibrin formation in a 
proportional dose-dependent manner,18–20 and to reduce 
whole blood viscosity.20,21
Finally, in patients with unstable angina (UA) or acute 
ST-segment elevation myocardial infarction (STEMI), 
parnaparin was able to reduce platelet count to a lesser extent 
than UFH.22,23
Pharmacokinetics
As with other LMWHs, the assessment of the main pharma-
cokinetic properties after administration of a single dose of 
parnaparin have been made indirectly ex vivo by measuring 
anti-Xa activity, considered to be the main antithrombotic 
mechanism.
In healthy volunteers the peak inhibition of factor 
Xa (Emax) after subcutaneous administration of parnaparin 
is dose-dependent (0.27 IU/mL after administration of 
3200 IUaXa, 0.58 IU/mL with 6400 IUaXa).10–12 After 
intravenous administration Emax is approximately 5-fold 
greater than after subcutaneous administration of the same 
dose (eg, mean Emax 1.35 IU/mL after iv administration of 
3200 IUaXa).10,12 Parnaparin peak anti-Xa activity (tmax) 
occurs rapidly after administration, approximately 3 hours 
and 5 minutes when the subcutaneous or intravenous route 
are used, respectively, regardless of dose.10,12 Independently 
of the injection site (abdomen, gluteal region, deltoid), 
the bioavailability of the drug was 90%.24,25 No signs of 
drug accumulation after repeated once-daily subcutaneous 
administration for 7 days were detected.26
Parnaparin is metabolized in the liver and kidneys and, 
as with other LMWHs, is cleared principally by the renal 
route;3 however, the effects of renal or hepatic impairment 
on its pharmacokinetics have not been reported. In general, Vascular Health and Risk Management 2009:5 821
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the clearance of the anti-Xa effect of LMWHs is strongly 
related to the creatinine clearance (CrCl), the cutoff value 
to avoid accumulation being a ClCr  30 mL/min, and renal 
insufficiency is associated with an increased risk of bleeding 
complications when therapeutic doses of LMWHs are used. 
Conversely, the administration of prophylactic doses is not 
reported to confer an higher bleeding risk.27 Therefore, it is 
likely that prophylactic doses of parnaparin may be safely 
administered in patients with severe renal insufficiency; 
however, if therapeutic doses are needed, weight-adjusted 
low-doses of parnaparin or UFH (which is not cleared 
through the kidneys) should be used.3,27
Search strategy
We started with a Medline search, using the keyword 
“parnaparin” [All Fields], with the limit “human”, which 
yielded 23 papers published between 1993 and 2007, of 
which 5 were reviews. We also crosschecked the references 
of all relevant articles and reviews in order to retrieve more 
evidence. Finally, we asked Alfa Wasserman (Bologna, Italy) 
to provide us with all the documentation inherent to the 
clinical development of parnaparin.
Overview of therapeutic efficacy
Clinical experience with subcutaneous parnaparin in various 
clinical situations is summarized in Tables 1 to 5.
Prevention of venous thromboembolic 
disease (Table 1)
Subcutaneous parnaparin, administered once or twice daily 
at 3200 or 6400 IuaXa, was compared with placebo28,29 or 
subcutaneous UFH14–16,30–38 in 14 randomized or parallel 
group studies conducted in adult patients undergoing (major) 
general,15,28,29,32,34–37 orthopedic,16,30,33 cardiac,31 urologic38 
and vascular surgery.14 Parnaparin was also evaluated 
in 8 cohort studies22,39–45 of patients undergoing (major) 
general,39 vascular,40,41 urologic,42,43 gynecologic,44 minor 
orthopedic45 and bariatric22 surgery, in all of which it was 
administered once daily at 3200 or 6400 IUaXa, but in one45 
at 4250 IUaXa.
Of the studies using a randomized design, 228,29 were 
double-blind placebo-controlled studies, 138 was single-blind 
and the other 714,15,30,31,34,35,37 were open, due to different 
administration schedules. Randomized studies were 
conducted over 4,31 7,14,15,28,29,34,35,37,38 or up to 1430 days; in all 
parallel group studies, prophylactic treatment with parnaparin 
lasted for 716,32,33,36 days, and in cohort studies for 7,39,42–44 8,41 
9,40 1045 and 3022 days. Prophylactic therapy was generally 
initiated 2 hours before low- to medium-risk thromboembolic 
surgery, and 12 hours before high-risk surgery. In a cohort 
study of patients undergoing minor orthopedic procedures, 
parnaparin was initiated 3 to 9 hours postoperatively.45
The efficacy endpoints were: frequency of DVT, 
investigated  with  venography,  ultrasonography 
(continuous-wave Doppler, compression ultrasound, 
color-coded Doppler ultrasound), fibrinogen uptake test 
or plethysmography (impedance, strain-gauge); and the 
frequency of pulmonary embolism (PE), which was assessed 
with ventilation/perfusion lung scan or chest X-ray, if 
suspected on clinical grounds (Table 1).
In general, although the methodological quality of the 
trials published before 1990 was modest, subcutaneous 
parnaparin demonstrated to be effective in the preven-
tion of DVT and PE (Table 1). Specifically, subcutaneous 
parnaparin was at least as effective as UFH in preventing 
DVT across all clinical trials; and in two large studies in 
patients undergoing general surgery (n = 610, and n = 173, 
respectively),32,35 the incidence of DVT in the parnaparin 
(3200 or 6400 IUaXa once-daily) group was statistically 
significantly lower than in the UFH (5000 IU 2- or 3-times 
daily) group (3.2% vs 6.3%, P  0.05; and 1.1% vs 7.1%, 
P = 0.038, respectively).
The low number of events recorded did not allow 
meaningful statistical comparisons for the frequency 
of PE.
Treatment of deep-vein thrombosis 
(Table 2)
Subcutaneous parnaparin, administered once or twice daily 
at 6400 or 12,800 IuaXa, was compared with intravenous46 
or subcutaneous47,48 UFH, or with nadroparin49 in 4 random-
ized trials of adult patients with objectively proven DVT. 
In all studies parnaparin was at least as effective as the 
comparator in preventing recurrent extending DVT and PE, 
with a similar safety profile. The short duration of patient 
observation (at most 6 months), combined with the choice 
of noninvasive tests to assess the endpoints (frequency of 
recurrent/extending DVT, and frequency of PE) is very likely 
responsible for the low frequency of events observed.
Chronic venous disease (Table 3)
The efficacy of parnaparin in the treatment of postphlebitic 
syndrome or chronic venous insufficiency of the lower 
limbs was compared with that of UFH in 5 randomized 
trials.51–55 Treatment duration ranged from 30 to 90 days. 
These small-sample (number of patients included = 46 to 92) Vascular Health and Risk Management 2009:5 822
Camporese et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
1
 
C
l
i
n
i
c
a
l
 
e
x
p
e
r
i
e
n
c
e
 
w
i
t
h
 
p
a
r
n
a
p
a
r
i
n
 
f
o
r
 
p
r
o
p
h
y
l
a
x
i
s
 
o
f
 
v
e
n
o
u
s
 
t
h
r
o
m
b
o
e
m
b
o
l
i
s
m
A
u
t
h
o
r
Y
e
a
r
S
e
t
t
i
n
g
D
e
s
i
g
n
E
n
d
-
p
o
i
n
t
 
a
s
s
e
s
s
m
e
n
t
P
a
t
i
e
n
t
s
a
P
a
r
n
a
p
a
r
i
n
 
 
(
I
U
a
X
a
)
 
s
c
C
o
m
p
a
r
a
t
o
r
T
r
e
a
t
m
e
n
t
 
d
u
r
a
t
i
o
n
F
o
l
l
o
w
-
u
p
D
e
e
p
-
v
e
i
n
 
t
h
r
o
m
b
o
s
i
s
b
P
u
l
m
o
n
a
r
y
 
e
m
b
o
l
i
s
m
b
B
l
e
e
d
i
n
g
†
V
e
r
a
r
d
i
 
e
t
 
a
l
3
2
1
9
8
8
M
a
j
o
r
 
g
e
n
e
r
a
l
 
s
u
r
g
e
r
y
P
G
R
F
U
T
,
 
C
w
D
,
 
S
G
P
,
 
 
V
6
1
0
 
(
3
0
8
/
3
0
2
)
3
2
0
0
 
o
r
 
6
4
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
b
i
d
 
o
r
 
t
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
3
.
2
/
6
.
3
 
(

0
.
0
5
)
0
.
3
2
/
1
.
0
 
(

0
.
0
5
)
0
.
9
7
/
3
.
6
 
(
0
.
0
3
2
)
G
o
s
s
e
t
t
i
 
e
t
 
a
l
4
0
1
9
8
8
V
a
s
c
u
l
a
r
 
 
s
u
r
g
e
r
y
C
R
F
U
T
,
 
C
w
D
,
 
U
S
4
0
6
4
0
0
 
o
d
–
9
 
d
a
y
s
n
o
n
e
2
.
5
N
R
N
R
G
r
u
t
t
a
d
a
u
r
i
a
 
e
t
 
a
l
3
6
1
9
8
8
G
e
n
e
r
a
l
 
 
s
u
r
g
e
r
y
P
G
R
F
U
T
,
 
C
w
D
1
7
9
 
(
8
9
/
9
0
)
3
2
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
b
i
d
7
 
d
a
y
s
n
o
n
e
2
.
2
/
4
.
4
 
(
0
.
6
8
)
N
R
3
.
4
/
 
1
2
.
2
 
(
0
.
0
4
8
)
B
o
n
o
m
o
 
e
t
 
a
l
3
9
1
9
8
8
G
e
n
e
r
a
l
 
s
u
r
g
e
r
y
C
i
P
G
,
 
V
7
8
3
2
0
0
 
o
d
–
7
 
d
a
y
s
n
o
n
e
2
.
3
N
R
2
.
3
C
h
i
a
p
u
z
z
o
 
e
t
 
a
l
1
6
1
9
8
8
M
a
j
o
r
 
o
r
t
h
o
p
e
d
i
c
 
s
u
r
g
e
r
y
P
G
R
F
U
T
,
 
C
w
D
1
4
0
 
(
7
0
/
7
0
)
3
2
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
t
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
7
.
1
/
1
0
 
.
0
 
(
0
.
6
6
)
0
/
0
4
.
2
/
7
.
1
 
(
0
.
6
)
C
a
t
a
n
i
a
 
e
t
 
a
l
3
5
1
9
8
8
G
e
n
e
r
a
l
 
s
u
r
g
e
r
y
R
,
 
O
C
w
D
,
 
C
X
r
1
7
3
 
(
8
8
/
8
5
)
3
2
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
t
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
1
.
1
/
7
.
1
 
(
0
.
0
3
8
)
0
/
1
.
2
 
(
0
.
2
5
)
0
/
0
M
a
s
c
a
l
i
 
e
t
 
a
l
3
3
1
9
8
8
M
a
j
o
r
 
o
r
t
h
o
p
e
d
i
c
 
s
u
r
g
e
r
y
P
G
D
U
S
1
3
6
 
(
6
8
/
6
8
)
3
2
0
0
 
b
i
d
U
F
H
 
5
0
0
0
 
 
i
U
 
t
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
1
.
5
/
2
.
4
 
(
1
.
0
0
)
N
R
2
.
9
/
1
3
.
4
 
(
0
.
5
5
)
S
p
e
z
i
a
l
e
 
e
t
 
a
l
1
4
1
9
8
8
V
a
s
c
u
l
a
r
 
s
u
r
g
e
r
y
R
,
 
O
R
F
U
T
9
2
 
(
4
6
/
4
6
)
6
4
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
b
i
d
7
 
d
a
y
s
n
o
n
e
6
.
5
/
8
.
6
 
(
0
.
8
6
)
N
R
8
.
7
/
1
7
.
4
 
(
0
.
2
9
)
V
a
l
l
e
 
e
t
 
a
l
2
8
1
9
8
8
G
e
n
e
r
a
l
 
s
u
r
g
e
r
y
R
,
 
D
B
C
w
D
1
0
0
 
(
5
0
/
5
0
)
3
2
0
0
 
o
d
P
l
a
c
e
b
o
7
 
d
a
y
s
n
o
n
e
0
.
0
/
6
.
0
 
(
0
.
2
4
)
N
R
2
.
0
/
 
6
.
0
 
(
0
.
6
1
)
P
e
l
l
e
g
r
i
n
o
 
e
t
 
a
l
4
2
1
9
8
8
U
r
o
l
o
g
i
c
 
s
u
r
g
e
r
y
C
C
e
,
 
V
8
7
3
2
0
0
 
o
r
 
6
4
0
0
 
o
d
–
7
 
d
a
y
s
n
o
n
e
2
.
3
0
2
.
3
C
o
r
t
e
l
l
i
n
i
 
e
t
 
a
l
4
3
1
9
8
8
U
r
o
l
o
g
i
c
 
s
u
r
g
e
r
y
C
i
P
G
8
0
3
2
0
0
 
o
r
 
6
4
0
0
 
o
d
–
7
 
d
a
y
s
n
o
n
e
6
.
2
N
R
5
.
0
S
a
l
c
u
n
i
 
e
t
 
a
l
3
7
1
9
8
8
M
a
j
o
r
 
g
e
n
e
r
a
l
 
s
u
r
g
e
r
y
R
,
 
O
P
h
y
,
 
C
w
D
,
 
C
X
r
1
4
1
 
(
7
3
/
6
8
)
3
2
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
t
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
4
.
1
/
1
0
.
3
 
(
0
.
1
5
)
1
.
4
/
2
.
9
 
(
0
.
6
1
)
8
.
2
/
7
.
3
 
(
0
.
8
8
)
F
o
r
z
a
n
o
 
e
t
 
a
l
2
9
1
9
8
8
G
e
n
e
r
a
l
 
s
u
r
g
e
r
y
R
,
 
D
B
C
w
D
1
0
0
 
(
5
0
/
5
0
)
3
2
0
0
 
o
d
P
l
a
c
e
b
o
7
 
d
a
y
s
n
o
n
e
2
.
0
/
1
2
.
0
 
(
0
.
1
1
)
N
R
N
R
P
i
n
i
 
e
t
 
a
l
3
0
1
9
8
9
H
i
p
 
f
r
a
c
t
u
r
e
 
s
u
r
g
e
r
y
R
,
 
O
R
F
U
T
,
 
S
G
P
,
 
 
V
4
9
 
(
2
5
/
2
4
)
3
2
0
0
 
b
i
d
U
F
H
 
5
0
0
0
 
 
i
U
 
t
i
d
 
s
c
1
4
 
d
a
y
s
,
 
o
r
 
d
i
s
c
h
a
r
g
e
n
o
n
e
2
0
.
0
/
2
9
.
2
 
(
0
.
5
)
0
.
0
/
1
2
.
5
 
(
0
.
1
1
)
1
2
.
0
/
 
8
.
3
 
(
1
.
0
)
T
a
r
t
a
g
l
i
a
 
e
t
 
a
l
4
4
1
9
8
9
G
y
n
e
c
o
l
o
g
i
c
a
l
 
s
u
r
g
e
r
y
C
C
e
,
 
C
w
D
,
 
C
X
r
9
2
3
2
0
0
 
o
d
 
o
r
 
6
4
0
0
 
o
d
–
7
 
d
a
y
s
n
o
n
e
3
.
3
0
.
0
N
R
C
o
r
r
a
d
o
 
e
t
 
a
l
3
8
1
9
8
8
U
r
o
l
o
g
i
c
 
s
u
r
g
e
r
y
R
,
 
S
B
R
F
U
T
,
 
C
w
D
,
 
i
P
G
5
8
 
(
2
9
/
2
9
)
6
4
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
b
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
0
.
0
/
0
.
0
0
.
0
/
0
.
0
0
.
0
/
0
.
0
V
e
r
a
r
d
i
 
e
t
 
a
l
3
4
1
9
8
9
M
a
j
o
r
 
g
e
n
e
r
a
l
 
s
u
r
g
e
r
y
R
,
 
O
R
F
U
T
,
 
C
w
D
8
8
 
(
4
4
/
4
4
)
6
4
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
b
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
2
.
3
/
6
.
8
 
(
0
.
6
2
)
N
R
0
.
0
/
0
.
0
G
a
r
c
e
a
 
e
t
 
a
l
1
5
1
9
9
2
M
a
j
o
r
 
g
e
n
e
r
a
l
 
s
u
r
g
e
r
y
R
,
 
O
R
F
U
T
,
 
U
S
,
 
V
,
 
C
X
r
,
 
L
S
9
0
 
(
4
5
/
4
5
)
3
2
0
0
 
o
d
U
F
H
 
5
0
0
0
 
 
i
U
 
t
i
d
 
s
c
7
 
d
a
y
s
n
o
n
e
0
.
0
/
2
.
2
 
(
1
.
0
)
0
.
0
/
0
.
0
0
.
0
/
 
1
1
.
1
 
(
0
.
0
5
6
)
G
o
s
s
e
t
t
i
 
e
t
 
a
l
4
1
1
9
9
2
M
a
j
o
r
 
v
a
s
c
u
l
a
r
 
s
u
r
g
e
r
y
C
R
F
U
T
,
 
U
S
6
5
3
2
0
0
 
o
d
–
8
 
d
a
y
s
n
o
n
e
1
.
5
N
R
1
.
5Vascular Health and Risk Management 2009:5 823
Clinical use of parnaparin Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
trials failed to show any statistically significant difference in 
terms of efficacy between parnaparin and UFH; although both 
parnaparin and UFH were generally effective in improving 
clinical and instrumental outcomes evaluated at baseline 
and at the end of treatment.51,53–55 In one double-blind 
study,52 parnaparin (6400 IUaXa) proved to be statistically 
significantly better than UFH and than a lower parnaparin 
dose (3200 IUaXa) in reducing the intensity of symptoms 
(evaluated on a clinical scale), the ankle diameter, and in 
increasing venous outflow (as assessed by strain-gauge 
plethysmography).
Peripheral arterial occlusive disease 
(Table 4)
Subcutaneous parnaparin (6400 IUaXa once-daily) was 
compared with placebo in 6 small (number of patients = 33 to 
36) randomized trials56–61 or with UFH in one nonrandomized 
study,13 performed over 656–61 or 713 months. All ran-
domized studies, except one58 were double-blinded, and 
conducted in patients with stage II disease (Leriche-Fontaine 
classification). Endpoints included the evaluation of pain-free 
walking distance (by treadmill) or time of rest and peak calf 
blood flow (by strain-gauge plethysmography), and of the 
ankle-brachial index (ratio between ankle and brachial artery 
pressures, normal ratio being 0.9).
In 4 of these studies56,58–60 parnaparin significantly 
improved pain-free walking distance or time, ankle-brachial 
index, or both, as compared to placebo. In the remaining 
3 studies,13,57,61 in which only within-group analysis was 
available, baseline values for pain-free walking distance, 
blood flow, or ankle-brachial index were significantly 
increased at the end of the treatment period in the parnaparin 
group57 or in both parnaparin and the UFH13 or placebo61 
groups, respectively.
Acute coronary syndromes (Table 5)
Parnaparin was compared with placebo in a small (n = 29), 
randomized, double-blind study of patients with stable 
angina,62 and with UFH in 2 large-sample randomized 
nonblinded trials of patients with unstable angina21 and 
STEMI.23
The two larger trials21,23 used composite efficacy hard 
endpoints, including death, while the smaller used only 
substitute endpoints.62 In the two larger trials, parnaparin 
yielded a statistically significant reduction in the frequency 
of the primary efficacy endpoint versus UFH,21,23 while in 
the smaller trial a statistically significant improvement in 
the primary efficacy endpoint was observed only in the 
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parnaparin group (no between-group comparisons available) 
versus placebo.62
Clinical update
Based on our search strategy, we were able to retrieve 1 full 
paper,63 and 2 congress abstracts64,65 dealing with clinical uses 
of parnaparin which were published during 2008. The first, a 
small-sample (n = 10) open-label study,63 evaluated the efficacy 
of 3 different oral dosages (70, 140 and 210 mg once daily) 
of parnaparin in the treatment of mild-to-moderate relapse 
of left-sided ulcerative colitis, over 8 weeks. The endpoints 
were standardized clinical and endoscopic activity of the 
disease. At the end of the treatment, 7 patients (70%) were 
in clinical remission, only 1 achieving endoscopic healing, 
and standardized clinical scores were statistically significantly 
improved from baseline. The second, a randomized open mul-
ticenter dose-finding study of patients (n = 66) with severe 
obesity (BMI  36) undergoing bariatric surgery, evaluated 
the effect of 2 parnaparin doses (4250 IUaXa or 6400 IUaXa, 
administered once daily for 9 ± 2 days) on anti-Xa levels, 
evaluated the day before operation, and at 4 and at 6 days after 
operation. The authors observed that with the administration 
of 4250 IUaXa the anti-Xa levels were within the expected 
activity range in 98.3% of the cases, while with 6400 IUaXa 
the anti-Xa activity was above the specified prophylactic range 
in 62.3 of the cases.64 The third study reported the results 
of a multicenter, randomized, double-blind, controlled trial 
comparing the efficacy and safety of aspirin (100 mg/daily 
for 3 months) versus parnaparin (12,800 IUaXa for 7 days 
followed by 6400 IUaXa for a total of 3 months) for treat-
ment of retinal vein occlusion (RVO). The primary efficacy 
endpoint of the study was the incidence of functional worsen-
ing of the eye with RVO at 6 months, objectively assessed by 
fluorescein angiography, visual acuity and visual field. The 
endpoint was adjudicated in 20.7% of patients treated with 
parnaparin (n = 28) and in 59.4% of patients treated with 
aspirin (n = 30) (P = 0.002). Recurrent RVO was diagnosed 
in 3 patients, all treated with aspirin (P = ns). Bleeding rates 
were similar between the two groups. Due to the small sample 
size of patients, the authors concluded that these promising 
results need to be confirmed in a larger clinical trial.65
No clinical studies using parnaparin during 2009 
were retrieved, but we are aware of an ongoing phase 3 
Italian multicenter randomized clinical trial (STEFLUX 
trial, all active recruiting centers located in Italy) on the 
treatment of superficial thrombophlebitis. The study 
compares the efficacy and safety of 3 different doses of 
parnaparin (8500 IUaXa subcutaneous, once daily for 
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10 days followed by placebo for 20 days versus 8500 IUaXa 
subcutaneous, once daily for 10 days, followed by 
6400 IUaXa subcutaneous, once daily for 20 days; versus 
4250 IUaXa subcutaneous, once daily for 30 days), and the 
planned sample size exceeds 1000 patients.
Tolerability and management
In all clinical trials in which parnaparin was investigated, 
a general good tolerability was reported. As with the 
other commercially available LMWHs, the most impor-
tant side effect was bleeding, usually classified as major 
(heavy blood loss, such as clinically overt hemorrhage 
associated with hemoglobin drop of at least 2 g/L or 
requiring the transfusion of 2 or more units of packed red-
blood cells; or bleeding at life-threatening sites, such as 
retroperitonal or intracranial events; or bleeding requiring 
re-intervention) or minor (including, for example, bleeding 
at the injection site).21,23 Studies of thromboprophylaxis 
after major surgery reported of an incidence of hemor-
rhagic complications ranging from 1% to 4%, whereas in 
studies dealing with parnaparin use in unstable angina, a 
3% incidence of minor bleeding and only 1 major bleed-
ing were observed.15,21,28,32 In a study considering patients 
with STEMI, bleedings events occurred in 3% of patients 
receiving parnaparin.23 After minor orthopedic surgery, 
bleeding complications were reported in 2% of the 
509 patients investigated, most of which were minor bleed-
ings (injection site hematomas).45
In studies evaluating the use of parnaparin in peripheral 
vascular diseases or chronic venous disorders, minor bleeding 
complications and/or pain occurred less in patients allocated 
to subcutaneous parnaparin than in those randomized to 
subcutaneous UFH.13,32,55,66
Heparin-induced thrombocytopenia (HIT) is another 
well known complication of heparin, its incidence 
being approximately 0.8%, with LMWH, about 3-fold 
lower than with UFH.67,68 HIT is caused by heparin-
dependent antibodies (usually immunoglobulin G) binding 
a confirmationally modified epitope on platelet factor 4 
(PF4), its modified structure being subsequently recognized 
as a foreign protein by the immunocompetent cells of the 
patients. HIT was not observed in any of the clinical trials of 
parnaparin discussed in this review. Nonetheless, patients 
receiving either a prophylactic or a therapeutic course of 
parnaparin are recommended to carefully monitor their 
platelet count during the first 2 weeks of exposure to the drug, 
especially those with a recent history of heparin exposure, 
who are at higher risk of developing HIT.5
Parnaparin is administered at different dosage accord-
ing to the type and the severity of the disease. Doses and 
administration of parnaparin in different clinical settings are 
shown in Table 6. Caution should be used in patients with 
renal or hepatic insufficiency, arterial hypertension, or any 
organ lesion subject to bleeding.5
Place in therapy and conclusion
In VTE prevention, parnaparin administered subcutaneously 
(3200 UIaXa) once daily for 7 days showed to be more 
effective than placebo (0% versus 6%, respectively) and at 
least as effective as UFH, in patients undergoing abdominal, 
vascular, orthopedic (major and minor) or cardiac surgery.
Compared to UFH, the equivalent efficacy of parnaparin 
given once daily for up to 3 months has been demonstrated in 
the treatment of CVD (above all chronic venous insufficiency 
secondary to a post-thrombotic syndrome), superficial 
trombophlebitis and DVT.
Table 6 Dosage and administration of parnaparin in different clinical settings
Setting Dose, UIaXa Route and frequency
Treatment of CVD, SVT,   VPH 3200 to 6400 sbc, od for 20–30 d
DVT prevention in general nonhigh risk surgery 3200 sbc, od 2 h before surgery, then for at least 7 d
DVT prevention in general high risk surgery, or orthopedic 
surgery
4250 sbc, od 12 h before surgery 12 h after surgery, 
at least for 10
DVT treatment 12800  
6400  
4250–6400
iv slow, for 3–5 d sbc, 
tid for at least 7–10 d sbc,  
od for 10–20 d
Unstable angina 6400 sbc, od for 7 d
STeMi 4250 sbc, tid for 7 d
PAOD 6400 sbc, od for 6 m
Abbreviations: CVD, chronic venous diseases; SVT, superficial vein thrombophlebitis;   VPH, varicophlebitis; DVT, deep vein thrombosis; STEMI, ST-segment elevation myocardial 
infarction; PAOD, peripheral arterial occlusive disease; sbc, subcutaneous; od, once-daily; tid, twice-daily; d, days; m, months.Vascular Health and Risk Management 2009:5 829
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In patients with stable angina a 3-month course of therapy 
with parnaparin provides a significant improvement in the exer-
cise time on treadmill test compared with baseline, but not in 
patients receiving placebo. Recently, in patients with unstable 
angina or STEMI, once-daily subcutaneous parnaparin has been 
shown to be able to significantly reduce the primary efficacy 
composite endpoint of death, acute MI or need for emergency 
myocardial revascularization (including coronary artery bypass 
grafting or angioplasty) in the first 7 days or 45 days after the 
start of treatment, respectively, compared to UFH (7% vs 11%, 
P = 0.034; 27% vs 42%, P = 0.03, respectively).
Subcutaneous parnaparin has been compared with placebo 
or UFH in patients with stage II PAOD (Leriche-Fontaine 
Classification). Compared with both placebo or UFH, 
parnaparin was able to significantly improve all the endpoints 
investigated, such as pain-free walking time and pain-
free walking distance, peak blood flow in the calf and the 
ankle-brachial index.
Tolerability of parnaparin has been generally reported 
across all studies. The risk of bleeding complications aris-
ing from parnaparin compared with UFH seems similar for 
the major bleeds, whereas the incidence of minor bleeds is 
lower with parnaparin.
No cases of HIT are reported with parnaparin use. 
However, a platelet count should be taken every 3 days 
for the first 2 weeks of treatment in all patients receiving 
parnaparin.
As with other LMWHs, and in contrast to UFH, 
parnaparin enables patients with most peripheral vascular 
diseases to be treated at home or as an outpatient because 
treatment is easy to manage, has good tolerability, equivalent 
efficacy and safety.
Further applications of parnaparin have been recently 
investigated in different settings (ulcerative colitis, RVO, 
severe obese patients undergoing bariatric surgery), even 
though its promising results on efficacy need to be confirmed 
in larger clinical trials.
In conclusion, parnaparin is a safe, effective, well tolerated 
LMWH widely investigated and used in the prevention and 
treatment of VTE, and in the management of CVD and of 
coronary artery disease. As with other LMWHs, parnaparin 
can be administered subcutaneously, once daily, with a better 
local tolerability than UFH, and the available data indicate 
that parnaparin could be the optimal choice among all the 
commercially available LMWHs.
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